OncoSynergy Announces First Patient Treated in First-in-Human Clinical Trial of OS2966 in Recurrent Glioblastoma
OncoSynergy, Inc., a physician-founded oncology company committed to advancing therapeutics to address dire unmet medical needs, announced today that the first patient was treated in the Company's First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida. OS2966 is a first-in-class immunotherapy, and the first ever anti-CD29 (beta 1 integrin) therapeutic to reach human trials.
Publication of a Health Economic Analysis Demonstrates IsoPSA® Significantly Reduces Unnecessary Prostate Cancer Biopsies and Costs
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company focused on the development of next-generation diagnostic tests for early detection of cancers, announced today the publication of a health economic analysis in Urology Practice. The publication demonstrates the cost effectiveness and economic utility of Cleveland Diagnostics’ IsoPSA test for the detection of clinically significant prostate cancer
First surgical case launches multicenter prospective clinical study of FDA-cleared product to support international market entry
Centerline Biomedical, Inc. (Centerline) announced Tuesday the completion of the first surgical case in its MOTION clinical study of its innovative Intra-Operative Positioning System (IOPS™) surgical navigation platform. The FDA-cleared technology is already being deployed in a controlled launch at Cleveland Clinic and other leading institutions in the United States. The MOTION study will be used to support the company’s submission for market clearance in Europe and other international markets.
NeuroTherapia Announces Completion of Phase 1a Clinical Trial
NeuroTherapia, Inc., a clinical-stage company focused on developing therapies for neurodegenerative diseases, announced today the completion of its first-in-human study of NTRX-07. This study was a single ascending dose clinical trial carried out in healthy volunteers.
Third Frontier awards $2.4 million to Northeast Ohio universities and companies
The Ohio Third Frontier Commission has awarded $2.4 million to two Northeast Ohio universities and eight companies to help them advance new technologies into the marketplace. The funds were part of $5.34 million the state program awarded to universities and businesses across the state from its Technology Validation and Start-up Fund (TVSF).
Cleveland Diagnostics Announces FDA Breakthrough Device Designation for Novel Prostate Cancer Diagnostic Test
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the early detection of cancers, announced today that it has received FDA Breakthrough Device Designation for the IsoPSA® Assay, a novel prostate cancer diagnostic test. Published studies from multicenter prospective clinical trials suggest that the non-invasive, blood-based IsoPSA assay has significant superior diagnostic accuracy when compared to traditional prostate-specific antigen (PSA) tests in detecting high-grade prostate cancer.
Xealth adds Atrium Health, Cleveland Clinic and MemorialCare to close $14m Series A
Xealth, the leading platform for connecting digital health, today announced that it has secured an additional $3 million in its Series A financing, bringing the amount raised in this round to $14 million total. New investors Atrium Health, Cleveland Clinic and MemorialCare Innovation Fund join McKesson Ventures, Novartis, Philips, ResMed, Threshold Ventures (formerly DFJ Venture), Providence Ventures, UPMC and Froedtert and the Medical College of Wisconsin health network. Investments from this round will be used to advance the development and deployment of the Xealth platform for digital health programs.
Catapult, Prevent Biometrics Partner to Sync Safety, Performance Data
In conducting extensive trials with college and high school sports teams, Prevent Biometrics found value in syncing the impact data gleaned from its smart mouthguards with game video to provide context on collisions.
Cleveland Diagnostics Announces Publication of Multicenter IsoPSA Clinical Validation Study Demonstrating Improved Accuracy Over Prostate-Specific Antigen Test
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary study published earlier in European Urology, demonstrating that the non-invasive, blood-based IsoPSA assay has superior diagnostic accuracy over the current gold standard, prostate-specific antigen (PSA), in detecting high-grade prostate cancer.
Cleveland Clinic spinoff company to start clinical trials for Alzheimer's disease
Cleveland Clinic spinoff company NeuroTherapia Inc. will start clinical trials of a new drug targeting inflammation of the brain that's found in Alzheimer's and other neurological diseases, according to a news release.